The pharmacokinetics of cytarabine in dogs when administered via subcutaneous and continuous intravenous infusion routes

Journal of Veterinary Pharmacology and Therapeutics

Volumn 36, Issue 4, 2013, Pages 408-411

  Crook, K I ^a   Early, P J ^a   Messenger, K M ^a   Munana K R ^a   Gallagher, R ^a   Papich, M G ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTINUOUS INFUSION; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; EXPERIMENTAL DOG; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LONG TERM EXPOSURE; MAXIMUM PLASMA CONCENTRATION; MENINGOENCEPHALITIS; NONHUMAN; PRIORITY JOURNAL; STEADY STATE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AREA UNDER CURVE; CROSS-OVER STUDIES; CYTARABINE; DOGS; HALF-LIFE; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS;

CANIS FAMILIARIS;

EID: 84880035701     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/jvp.12008     Document Type: Article

References (22)

1. Behr, S, Llabres-Dias, FJL & Radaelli, ST (2009) Treatment of meningoencephalitis of unknown origin in a dog. Veterinary Record, 164, 627-629.
2. Coates, JR, Barone, G, Dewey, CW, Vitale, CL, Holloway-Azene, NM & Sessions, JK (2007) Procarbazine as adjunctive therapy for treatment of dogs with presumptive antemortem diagnosis of granulomatous meningoencephalomyelitis: 21 cases (1998-2004). Journal of Veterinary Internal Medicine, 21, 100-106.
3. Cuddon, PA, Coates, JR & Murray, M (2002) New Treatments for Granulomatous Meningoencephalomyelitis. Proceedings 20th ACVIM Forum, 319-321.
4. Fagerholm, U (2007) The highly permeable blood-brain barrier: an evaluation of current opinions about brain uptake capacity. Drug Discovery Today, 12, 1076-1082.
5. Ho, DHW, Carter, CJK, Loo, TL, Abbott, RL & McBride, CM (1975) Pharmacologic Studies of cyclocytidine and arabinosylcytosine in dogs. Drug Metabolism and Disposition, 3, 309-313.
6. Kipar, A, Baumgartner, W, Vogl, C, Gaedke, K & Wellman, M (1998) Immunohistochemical characterization of inflammatory cells in the brains of dogs with granulomatous meningoencephalitis. Veterinary Pathology, 35, 43-52.
7. Kufe, D, Munroe, D, Herrick, D, Egan, E & Spriggs, D (1984) Effects of1-beta-D-arabinofuranosylcytosineincorporation of eukaryotic DNA template function. Molecular Pharmacology, 26, 128-134.
8. Kuusela, E, Raekallio, M, Anttila, M, Falck, I, Mölsä, S & Vainio, O (2000) Clinical effects and pharmacokinetics of medetomidine and its enantiomers in dogs. Journal of Veterinary Pharmacology and Therapeutics, 23, 15-20.
9. Major, P, Egan, EM, Herrick, D & Kufe, D (1982) The effect of ara-C incorporation on DNA synthesis. Biochemical Pharmacology, 31, 2937.
10. Menaut, P, Landart, J, Behr, S, Lanore, D & Trumel, C (2008) Treatment of 11 dogs with meningoencephalomyelitis of unknown origin with a combination of prednisolone and cytosine arabinoside. Veterinary Record, 162, 241-245.
11. Nuhsbaum, MT, Powell, CC, Gionfriddo, JR & Cuddon, PA (2002) Treatment of granulomatous meningoencephalomyelitis in a dog. Veterinary Ophthalmology, 5, 29-33.
12. Riviere, JE (2011) Comparative Pharmacokinetics: Principles, Techniques, and Applications, 2nd edn. pp. 18-19. Wiley-Blackwell, Iowa.
13. Rustum, YM, Riva, C & Preisler, HD (1987) Pharmacokinetic parameters of 1-ß- arabinofuranosylcytosine (ara-C) and their relationship to intracellularmetabolism of ara-C, toxicity, and response of patients with acute non-lymphocytic leukemia treated with conventional and high-dose ara-C. Seminars Oncology, 14, 157-168.
14. Salonen, S, Vuorilehto, L, Vainio, O & Anttila, M (1995) Atipamezole increases medetomidine clearance in the dog: and agonist-antagonist interaction. Journal of Veterinary Pharmacology and Therapeutics, 18, 328-332.
15. Schatzberg, SJ (2005) An update on Granulomatous meningoencephalitis, necrotizing meningoencephalitis and necrotizing leukoencephalitis. Proceedings of the 23rd American College of Veterinary Internal Medicine Forum, 351-353.
16. Scott-Moncrieff, JCR, Chan, CK, Samuels, ML, Cook, JR, Coppoc, GL, DeNicola, DB & Richardson, RC (1991) Plasma and cerebrospinal fluid pharmacokinetics of cytosine arabinoside and dogs. Cancer Chemotherapy and Pharmacology, 29, 13-18.
17. Sorjonen, DC (1992) Myelitis and meningitis. Veterinary Clinics of North America Small Animal Practice, 22, 951-964.
18. Spriggs, D, Griffin, J, Wisch, J & Kufe, D (1985) Clinical pharmacology of low-dose cytosine arabinoside. Blood, 65, 1087-1089.
19. Talarico, LR & Schatzberg, SJ (2010) Idiopathic granulomatous and necrotising inflammatory disorders of the canine central nervous system: a review and future perspectives. Journal of Small Animal Practice, 51, 138-149.
20. Tipold, A (1995) Diagnosis of inflammatory and infectious diseases of the central nervous system in dogs: a retrospective study. Journal of Veterinary Internal Medicine, 9, 304-314.
21. Yoon, H, Taeg, SK & Braciale, TJ (2010) The cell cycle time of CD8+ T cells responding in vivo is controlled by the type of antigenic stimulus. PLoS One, 5, e15423.
22. Zarfoss, M, Schatzberg, S, Venator, K, Cutter-Schatzberg, K, Cuddon, P, Pintar, J, Weinkle, T, Scarlett, J & DeLahunta, A (2006) Combined cytosine arabinoside and prednisone therapy for meningoencephalitis of unknown aetiology in 10 dogs. Journal of Small Animal Practice, 47, 588-595.